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Abstract
Successful amelioration of cardiac dysfunction and heart failure through gene therapy approaches will require a
transgene effective at attenuating myocardial injury, and subsequent remodeling, using an efficient and safe
delivery vehicle. Our laboratory has established a well-curated, high-quality repository of human myocardial
tissues that we use as a discovery engine to identify putative therapeutic transgene targets, as well as to better
understand the molecular basis of human heart failure. By using this rare resource we were able to examine age-
and sex-matched left ventricular samples from (1) end-stage failing human hearts and (2) nonfailing human
hearts and were able to identify the X-linked inhibitor of apoptosis protein (XIAP) as a novel target for treating
cardiac dysfunction. We demonstrate that XIAP is diminished in failing human hearts, indicating that this potent
inhibitor of apoptosis may be central in protecting the human heart from cellular injury culminating in heart
failure. Efforts to ameliorate heart failure through delivery of XIAP compelled the design of a novel adeno-
associated viral (AAV) vector, termed SASTG, that achieves highly efficient transduction in mouse heart and in
cultured neonatal rat cardiomyocytes. Increased XIAP expression achieved with the SASTG vector inhibits
caspase-3/7 activity in neonatal cardiomyocytes after induction of apoptosis through three common cardiac
stresses: protein kinase C-c inhibition, hypoxia, or b-adrenergic receptor agonist. These studies demonstrate the
potential benefit of XIAP to correct heart failure after highly efficient delivery to the heart with the rationally
designed SASTG AAV vector.
Introduction
Heart failure affects an estimated 5.7 million Ameri-cans, with approximately 300,000 deaths per year (Roger
et al., 2012a,b). The chronic and disabling nature of heart
failure places an extreme economic burden on health care
resources, and given the predicted increasing incidence of
heart failure, the problem will only worsen. Gene therapy is a
promising therapeutic option for heart failure (Williams and
Koch, 2004; Whelan et al., 2010; Pacak and Byrne, 2011; Wasala
et al., 2011). Ongoing clinical trials for the correction of cardiac
diseases have demonstrated tolerability, safety, and biological
effects, but further advances in gene therapy for heart failure
are still required for its widespread use. Here we report on our
efforts to identify and characterize a new molecular target for
heart failure as well as our efforts to significantly improve
adeno-associated viral (AAV) capsid design enabling more
efficient cardiac gene delivery. Together, these two factors
may enable more successful gene therapy for heart failure.
Many conditions may lead to heart failure. However, ap-
optosis or programmed cell death has been implicated as a
common underlying, cellular process involved in many
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forms of human heart disease (Masri and Chandrashekhar,
2008). Much of the progressive deterioration of cardiomyo-
cyte function during heart failure as well as cardiomyocyte
damage during ischemia reperfusion is thought to occur
because of apoptosis. In humans, it has been estimated that
the apoptotic index in nonfailing human hearts is less than
0.5% whereas in heart disease or heart failure, it is increased
2- to 100-fold (Khoynezhad et al., 2007). Interruption of the
apoptotic pathway, either at the initial cardiac insult or
during the progression of the disease, may have the potential
to ameliorate many forms of cardiomyopathies. To date there
has been a paucity of experimental attempts to modify the
apoptotic cascade in models of heart disease, and this strat-
egy has not been studied clinically (Laugwitz et al., 2001;
Chatterjee et al., 2002; Okada et al., 2005, 2009).
Cysteine-aspartic proteases, or caspases, the downstream
effector molecules activated in apoptosis, trigger lethal
events in both the cytoplasm and the nucleus (Czerski and
Nunez, 2004; Regula and Kirshenbaum, 2005; Zorc-Pleskovic
et al., 2006; Gustafsson and Gottlieb, 2008; Masri and Chan-
drashekhar, 2008). Caspase-3, the terminal enzyme in this
cascade, resides as a proenzyme until activated by upstream
enzymes such as caspase-8, caspase-9, or granzyme. Cas-
pase-3 levels, and activity, are regulated by a family of
proteins termed inhibitors of apoptosis proteins (IAPs)
(O’Riordan et al., 2008). Although eight distinct human IAPs
have been described in the literature (O’Riordan et al., 2008),
the X-linked inhibitor of apoptosis protein (XIAP) is con-
sidered the most potent as it directly inhibits the enzymatic
activities of not only caspase-3 but also of caspases 7 and 9
(O’Riordan et al., 2008). In addition, XIAP contains E3 ubi-
quitin ligase activity, which can promote the ubiquitination
of caspase-3, further decreasing caspase-3 activity (O’Rior-
dan et al., 2008).
Here, we demonstrate that XIAP expression is diminished
in failing human hearts compared with nonfailing controls.
Therefore, a goal of this study was to mitigate putative ap-
optotic effects through efficient delivery, and expression, of
XIAP. The ideal vector for this study would minimally im-
pact the apoptosis cascade, provide high-level, long-term
gene expression, and be safe for eventual clinical use. Adeno-
associated viral (AAV) vectors meet many of these require-
ments and are rapidly becoming vectors used in clinical trials
for cardiovascular gene delivery (Hajjar et al., 2008; Jaski
et al., 2009; Gwathmey et al., 2011). Ongoing in the AAV field
is the identification of AAV serotypes or the development of
AAV capsid variants that render high-level transduction in
target organs such as skeletal and cardiac muscle (Du et al.,
2004; Wang et al., 2005; Su et al., 2006, 2008; Palomeque et al.,
2007; Bish et al., 2008a,b; Zincarelli et al., 2008; Tarantal and
Lee, 2009; Yang et al., 2009; Pulicherla et al., 2011). Previously,
by using a rational design approach we were able to identify
five amino acids of the AAV1 capsid as responsible for effi-
cient skeletal muscle transduction (Bowles et al., 2011). Here
we have evaluated the influence of these five amino acids,
engineered individually and in groups in the context of both
the AAV2 and AAV3b capsids, on the transduction of mu-
rine skeletal and cardiac muscle. The modification of two of
these amino acids in the AAV3b capsid rendered a capsid
exhibiting extremely high-level cardiac muscle transduction.
Using this novel AAV3b vector, termed SASTG, to deliver
the XIAP gene into rat neonatal cardiomyocytes, we dem-
onstrate that this potent apoptotic inhibitor attenuates
apoptosis induced by protein kinase C (PKC) inhibition,
hypoxia/ischemia, or isoproterenol stimulation. These stud-
ies demonstrate the development of an innovative AAV
vector (SASTG) for efficient delivery of a novel antiapoptotic
transgene (XIAP) with potential cardioprotective impact
during human heart failure.
Materials and Methods
Human myocardium acquisition
Human myocardium was obtained from unused ‘‘non-
failing’’ donor hearts and explanted hearts from cardiac
transplantation. All hearts were arrested in vivo, with cardi-
oplegia (4C). Anterolateral samples of the left ventricle were
then obtained and snap frozen in liquid nitrogen. The study
was approved by the Institutional Review Board at Duke
University Medical Center (Durham, NC).
Protein isolation and XIAP immunodetection
Left ventricular samples were placed in homogenization
buffer and homogenized while on ice. The homogenate was
centrifuged and the supernatant was used for study. All
protein homogenates were subjected to bicinchoninic acid
(BCA) assay (Pierce Biotechnology/Thermo Fisher Scientific,
Rockford, IL) for protein quantification. XIAP present in the
human myocardial lysate was quantified by Western blotting.
Protein samples (75 lg per lane) were electrophoresed on a
10–20% Tris–glycine gel (Invitrogen, Carlsbad, CA), trans-
ferred to a nitrocellulose membrane, and probed with a 1:500
dilution of mouse anti-XIAP antibody (BD Biosciences, San
Jose, CA) followed by a 1:2500 dilution of enhanced chemi-
luminescence (ECL) anti-mouse IgG horseradish peroxidase-
linked antibody (GE Healthcare Bio-Sciences, Piscataway,
NJ), and detected with detection reagent (GE Healthcare Bio-
Sciences). Nitrocellulose blots were stripped and reprobed
with a 1:500 diluted monoclonal anti-sarcomeric actin anti-
body (Sigma-Aldrich, St. Louis, MO). XIAP and actin signals
were quantified with ImageJ (National Institutes of Health
[NIH], Bethesda, MD) and XIAP expression levels were nor-
malized to actin. XIAP levels were also quantified with a
Proteome Profiler human apoptosis array kit as per the
manufacturer’s instructions (R&D Systems, Minneapolis,
MN). XIAP was quantified in duplicate from each homoge-
nate. Data are represented as raw optical units (ROU).
Plasmid and DNA mutagenesis
Starting plasmids for mutagenesis were the packaging
plasmids pXR2 and pXR3 (Rabinowitz et al., 2002). All
plasmid mutagenesis was performed with either a Quik-
Change multi site-directed mutagenesis or QuikChange site-
directed mutagenesis kit (both from Stratagene/Agilent
Technologies, Santa Clara, CA). Accuracy of the nucleotide
changes was verified by DNA sequence analyses followed by
DNA subcloning to eliminate any unwanted artifacts gen-
erated by the mutagenesis.
AAV vector development and production
The plasmid carrying the cDNA for human X-linked in-
hibitor of apoptosis (XIAP) was obtained from the American
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Type Culture Collection (ATCC, Manassas, VA). The XIAP
cDNA was excised from the ATCC shuttle plasmid, using
AgeI and NotI digestion, and then ligated into the pTR vector.
Recombinant XIAP-AAV, GFP-AAV, and Luciferase-AAV
vectors were generated by the standard triple transfection
method (reviewed in Grieger et al., 2006), using the XX6-80
adenoviral helper plasmid with packaging plasmid (pXR1-9,
Q263AT265, Q263A, T265, N705AV708AT716N, SASTG, or
3.1) and the TR plasmid carrying human XIAP, green fluo-
rescent protein (GFP) (pTRUFr; Zolotukhin et al., 1999), or
firefly luciferase transgenes. rAAV-XIAP, rAAV-luciferase,
and rAAV-GFP were purified by standard methodology
(reviewed in Grieger et al., 2006) and the physical titer
was evaluated by dot-blot hybridization (reviewed in
Grieger et al., 2006). The adenoviral luciferase vector was
obtained from the Pittsburgh Human Gene Therapy Center
(Pittsburgh, PA).
Animals
C57BL and BALB/c mice were purchased from Jackson
Laboratory (Bar Harbor, ME). Animals were maintained and
treated in accordance with the Animal Care and Use Com-
mittee of the University of North Carolina at Chapel Hill
(Chapel Hill, NC) (for skeletal muscle injections) or with the
Animal Care and Use Committee at Duke University (for
myocardial injections). All care and procedures were in ac-
cordance with the Guide for the Care and Use of Laboratory
Animals (DHHS Publication No. [NIH] 85-23), and all pro-
cedures received prior approval by either the University of
North Carolina or Duke University (Durham, NC) Institu-
tional Animal Care and Use Committee.
Skeletal muscle injections
A volume containing 1 · 1010 viral genome-containing
particles (VG) was injected into the gastrocnemius of male
BALB/c mice (6 to 8 weeks old). A total of six limbs per
experiment were injected for each vector type, using 25 ll of
virus. The mice were anesthetized by intraperitoneal ad-
ministration of 2.5% tribromoethanol (Avertin). A solution of
the luciferase substrate luciferin (150 mg/kg; Invitrogen) was
injected intraperitoneally. A gray-scale reference image of
animals was generated and mice were imaged for 5 min,
using a NightOWL cabinet with charge-coupled device
(CCD) camera (Berthold Technologies, Bad Wildbad, Ger-
many). Total photon emission from selected and defined
areas within the images of each mouse was quantified with
WinLight 32 software (Berthold Technologies). The photon
signal was presented as a pseudo-color image representing
light intensity. This image was superimposed on the refer-
ence image for orientation.
Direct myocardial injections
Four mice per vector type for each experiment were sub-
jected to myocardial injection with 2 · 1010 VG. To perform
the injections, mice were first anesthetized (a cocktail of ke-
tamine [100 mg/kg] and xylazine [2.5 mg/kg]) and intubated
(a blunt 20-gauge plastic needle connected to a rodent ven-
tilator at a tidal volume of 0.2 ml and a respiratory rate of
105 breaths/min). The chest cavity was entered via the third
intercostal space, with exposure of the left ventricle. Five to
10 ll of vector was injected into the anterior free wall of the
left ventricle. After the injection, the chest was closed;
pneumothorax was evacuated with a modified chest tube
made of PE-50 polyethylene with multiple distal side-holes.
The mice were extubated and allowed to recover from an-
esthesia. For imaging experiments, mice were anesthetized
with isoflurane. One hundred microliters of luciferin was
delivered via intraperitoneal injection, and animals were
imaged 10 min after injection, using a Xenogen IVIS imaging
system (Caliper Life Sciences/PerkinElmer, Hopkinton, MA)
and luminescence was measured. Data are presented as rel-
ative light units per region of interest (ROI).
Rat neonatal cardiomyocyte isolation
Neonatal rat cardiomyocytes were isolated from ventricles
of 2-day-old Sprague-Dawley rats (Charles River Labora-
tories, Wilmington, MA). Briefly, excised ventricles were
minced and incubated overnight in a 0.07% solution of
trypsin (Sigma-Aldrich) at 4C, followed by four-step dis-
sociation in 0.1% collagenase II (Worthington Biochemical,
Lakewood, NJ) at 37C (Pedrotty et al., 2009). Dissociated
cells were resuspended in culture medium (DMEM–F12
medium [Invitrogen] supplemented with 10% calf serum
[Colorado Serum Company, Denver, CO] and 10% horse
serum [HyClone/Thermo Fisher Scientific, Logan, UT]) and
preplated in two 1-hr steps to remove faster adhering non-
myocytes (Pedrotty et al., 2009).
Viral vector infections and experimental design
Neonatal cardiomyocytes plated at 10,000 cells per well
were placed in cardiac medium containing 2% fetal bovine
serum (FBS) 12 hr before infection with Ad-luciferase,
SASTG-luciferase, SASTG-GFP, or SASTG-XIAP. All phar-
macological treatments were performed on cells approxi-
mately 72 hr postinfection. All pharmacological treatments,
including vehicle controls, were done in duplicate or tripli-
cate. To induce apoptosis pharmacologically, chelerythrine
(Yamamoto et al., 2001) was added to the medium for 1 hr at a
final concentration of 1 lM. This dose has previously been
shown to induce caspase-3 activation and morphological cel-
lular changes indicative of apoptosis (Yamamoto et al., 2001).
For isoproterenol experiments, isoproterenol (1 lM) was ad-
ded to the media for 24 hr. For hypoxia–ischemia experiments,
two 6-well dishes were incubated inside an airtight container
at 37C. Cardiomyocytes were placed in standard medium in
a 95% O2–5% CO2 environment for 6 hr. The cells were then
placed in medium with the following composition: 118 mM
NaCl, 24 mM NaHCO3, 1 mM NaH2PO4, 2.5 mM CaCl2,
1.2 mM MgCl2, 2 mM sodium-l-lactate, 16 mM KCl, and
10 mM 2-deoxyglucose and the chamber was superfused with
1% O2, 5% CO2, and 94% nitrogen for 12 hr. The gas was then
switched back to 95% O2–5% CO2 for reoxygenation and the
medium was switched to Medium 199 containing 2% FBS
to reinstitute nutrients for 6 hr. Cells from all experiments
were lysed and assayed for total protein (BCA assay) before
assaying for caspase-3/7 activity.
Caspase-3/7 assay and firefly luciferase assay
Caspase-3/7 activity was measured with a Caspase-Glo
3/7 assay system (Promega, Madison, WI). Fifteen to 20 lg of
AAV-MEDIATED ANTIAPOPTOTIC CARDIOPROTECTION 637
human heart lysate or rat neonatal cardiomyocyte lysate was
added to a 96-well plate in the presence of the luminescent
substrate. Luminescence was measured every 15 min during
the 90-min observation period, using a Veritas luminometer
from Turner BioSystems (Sunnyvale, CA). The signal was
normalized to the protein loaded into each well. The ap-
propriate positive and negative controls were performed to
ensure that the majority of signal was from the lysates.
Firefly luciferase activity was measured with luciferase assay
reagent (Promega). Within the luminometer, wells were in-
jected with 100 ll of luciferase assay reagent, and after a
delay of 2 sec, a measurement was taken for 10 sec.
Statistics
Data are expressed as means followed by the standard
deviation. Normalized immunoblot and caspase-3/7 assay
data were compared by unpaired Student t test. A p value
less than 0.05 was considered statistically significant.
Results
Enhanced apoptosis in failing human hearts
is correlated with downregulation of XIAP,
an inhibitor of apoptosis
Loss of apoptotic regulation may contribute to cell death
leading to heart failure. Using tissue samples from a unique
repository of failing and nonfailing human hearts (estab-
lished by the authors in the Department of Surgery at Duke
University), relative levels of protein markers of apoptosis
were investigated. Because XIAP is a central modulator of
apoptosis, we hypothesized that deregulation of XIAP may
be a contributing factor in human heart failure. Protein
analysis of XIAP in failing human myocardium, compared
with nonfailing hearts, was assessed by two different assays.
Quantitation of protein levels by Western blot analysis
demonstrated a 38% decrease in XIAP expression in failing
human myocardium, compared with nonfailing controls
(Fig. 1A). In a complementary proteomics-based approach,
antibody arrays also confirmed the presence of a significant
loss of XIAP in failing hearts from four different individuals,
compared with nonfailing control hearts from four distinct
individuals (Fig. 1B and C). A statistically significant 33%
decrease in XIAP was shown in failing human myocardium,
using protein array technology (Fig. 1B and C). Importantly,
caspase-3/7 activity was inversely related to XIAP expres-
sion, wherein caspase-3/7 activity increased by 267% in
failing myocardium (Fig. 1D). Loss of XIAP expression may
result in enhanced caspase-3/7 activity, and consequently
increased cell death in failing human myocardium. There-
fore, commissioning therapeutic gene delivery approaches to
reconstitute XIAP expression in diseased human hearts may
mitigate cell death associated with apoptosis.
Development of an AAV3b-derived vector, SASTG,
that renders high-level cardiac tissue
and cardiomyocyte transduction
AAV-derived vectors are amenable to rational design
based on a combination of capsid structure predictions, se-
quence alignments, susceptibility to neutralizing antibodies,
and distinct functional capabilities (Bowles et al., 2011). The
diminished capacity of AAV2 and AAV3b to transduce
skeletal muscle make them amenable to gain-of-function
studies to test rationally designed capsid variants, as dem-
onstrated by the generation of AAV2.5 (Bowles et al., 2011).
Five amino acids (N705/V708/T716/Q263/T265), unique to
AAV1, endow AAV2 with the capacity to transduce mouse
skeletal muscle with greater efficiency than conventional
AAV2, approaching that of AAV1 (Bowles et al., 2011). Un-
derstanding that these five capsid amino acids dramatically
influence AAV vector biology, we wanted to further
FIG. 1. X-linked inhibitor of
apoptosis protein (XIAP) lev-
els and caspase-3/7 activity
in human heart failure. (A)
Quantitation of XIAP Wes-
tern blot as determined by
densitometry analysis and
expressed as raw optical
units (ROU) normalized to
actin levels. (B) Antibody ar-
ray approach showing XIAP
levels from four nonfailing
(NF) and four failing (F) hu-
man hearts. Duplicate spots
are presented for each heart.
(C) Quantitation of antibody
arrays by densitometry anal-
ysis, and expressed as raw
optical units. (D) Caspase-3/
7 activity in lysates from hu-
man nonfailing LV myocar-
dium (NF) or failing human
myocardium (F), and ex-
pressed as relative light units
normalized for total protein.
Bars represent the standard
deviation; *p < 0.05.
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investigate the biology of these capsid regions: (1) to assess
the contribution of individual amino acids to the efficiency of
AAV2 vector transduction and (2) to determine whether the
enhanced transduction imparted by these amino acids is
restricted to AAV2 or is part of a general transduction
mechanism that can be extended to other serotypes such as
AAV3b.
To investigate whether all five amino acids engineered
into AAV2.5 were necessary for its enhanced skeletal muscle
transduction two subvariants were generated, Q263A/T265
and N705A/V708A/T716N, and quantitated by in vivo
imaging (Fig. 2A). Except for T265 (an insertion), all amino
acid mutations were individual substitutions. Amino acid
groupings were derived from the structural assessment of
AAV2.5 (depicted in Bowles et al., 2011; see Fig. 1C therein).
Briefly, two capsid subunits meet at the 2-fold axis of sym-
metry where these five amino acids are in close proximity
with the N705A/V708A/T716N grouping on one side of the
axis and the Q263A/T265 grouping on the other. Figure 2A
demonstrates that the N705A/V708A/T716N subvariant
exhibited an inefficient skeletal muscle transduction profile,
similar in efficiency to the AAV2 vector (Bowles et al., 2011),
whereas the Q263A/T265 subvariant was up to 9.8-fold
more efficient. Further partitioning of the Q263A/T265
subvariant into AAV2 capsids with individual modifications,
Q263A and T265, revealed that only the one amino acid in-
sertion, T265, can confer on AAV2 the ability to transduce
skeletal muscle with enhanced efficiency (Fig. 2B). Thus, the
enhanced skeletal muscle transduction observed for AAV2.5
can be attributed primarily to the T265 insertion.
The rational identification of a portable capsid system that
can augment the muscular transduction profile of various
AAV serotypes may expand the availability of gene delivery
vehicles, and provide insight into specific AAV capsid re-
gions critical for transduction. Thus, the AAV3b capsid was
modified to resemble the AAV2 Q263A/T265 subvariant by
introducing these modifications at similar positions in the
AAV3b capsid, and termed SASTG to distinguish it from
conventional AAV3b. In vivo administration of SASTG to
skeletal muscle was quantitated by luciferase expression
at various times posttransduction (Fig. 2C). Intriguingly,
SASTG exhibited significantly enhanced skeletal muscle
transduction compared with conventional AAV3b, achieving
skeletal muscle transduction levels similar to AAV1 (Fig. 2C).
Further partitioning of SASTG to the single T265 insertion,
AAV3.1, did not reach SASTG transduction levels in skeletal
muscle (Fig. 2D). These results indicate that the Q263A/T265
subvariant group is necessary to fully augment transduction
of skeletal muscle for AAV3b (SASTG vector), whereas only
the T265 mutation was necessary for AAV2.
In skeletal muscle SASTG and the T265 AAV2 subvariants
achieved transduction efficiencies that approach those of
FIG. 2. Evaluation of skeletal muscle transduction by AAV variants, using biophotonic imaging. Skeletal muscle trans-
duction of (A) Q263AT265-luciferase and N705AV708AT716N-luciferase vectors was examined on days 3, 7, 21, 28, and 42
postinjection. (B) Q263A-luciferase and T265-luciferase vectors were examined on days 7, 14, 28, 42, 100, and 170 postin-
jection. (C) AAV1-, AAV2-, AAV3b-, and SASTG-luciferase vectors were examined on days 3, 7, 14, and 21. For each
experiment in (A), (B), and (C) each limb (n = 6 limbs per group) was injected with 1 · 109 genome particles in each gas-
trocnemius muscle. Data are expressed as relative light units per region of interest (RLU/ROI). (D) Comparison of skeletal
muscle transduction of AAV3, AAV3.1, and SASTG, using in vivo biophotonic imaging of hind leg injections. Increasing
wavelength reflects greater luminescence. Color images available online at www.liebertonline.com/hum
AAV-MEDIATED ANTIAPOPTOTIC CARDIOPROTECTION 639
AAV1. In rodent heart muscle AAV1, the closely related
AAV6 serotype, and AAV9 have been reported to mediate
higher levels of gene expression than AAV2 (Kawamoto et al.,
2005; Pacak et al., 2006; Su et al., 2006; Palomeque et al., 2007).
Studies comparing AAV6, AAV8, and AAV9 in nonhuman
primates indicate that AAV6 achieves the most efficient,
widespread, and most cardiac-specific gene expression in this
model (Gao et al., 2011). To investigate the potential that the
T265 AAV2 subvariant and SASTG may acquire a cardiac
muscle transduction profile similar to AAV1, AAV6, or
AAV9, vectors were directly administered to rodent hearts,
and transduction profiles were quantitated over time by lu-
ciferase expression (Fig. 3). Both AAV2 subvariants (Q263A/
T265 and T265) exhibited greatly enhanced cardiac muscle
transduction, compared with conventional AAV2 (Fig. 3A).
Surprisingly, SASTG attained transduction efficiencies that
were up to 21-fold greater than AAV1 (Fig. 3B). Compared
with AAV9, which also exhibits efficient cardiac transduction
(Pacak et al., 2006), SASTG was greater than 8-fold more ef-
ficient at cardiac muscle transduction in two independent
experiments (Fig. 3C and D). Importantly, when compared
with AAV9, expression arising from SASTG appears to re-
main localized in the heart (Fig. 3C), whereas expression
arising from AAV9 appears to spread from the initial site of
injection to other organs, such as the liver (Fig. 3C). In addi-
tion, the SASTG vector appears to achieve substantial ex-
pression by day 2 compared with the AAV9 vector (Fig. 3D).
Overall, SASTG exhibits more efficient transduction than
AAV1 or AAV9 on in vivo administration to cardiac tissue.
These studies were extended to test the transduction ca-
pacity of SASTG against a panel of AAV-luciferase vectors
representing conventional AAV serotypes 1–9. Rat neonatal
cardiomyocytes can be routinely isolated in our laboratory to
investigate cardiac function at the molecular and cellular
levels. To assess whether SASTG offered higher transduction
levels than other AAV serotypes, cardiomyocytes were
transduced with an equivalent number of genomes from
each AAV-luciferase vector. Of the serotypes tested, only
AAV1, AAV6, and SASTG rendered substantial increases in
luciferase expression (Fig. 4). In accordance with the in vivo
mouse imaging analysis, SASTG achieved the highest ex-
pression levels, which were 26-fold greater than AAV1 and
61-fold greater than AAV6 (Fig. 4). Clearly, SASTG would be
highly desirable for therapeutic transgene delivery to cardiac
tissue in vivo, as well as in vitro. Cardiac tissue delivery of
XIAP with the AAV3b-derived SASTG vector may alleviate
apoptotic effects that contribute to heart failure.
Delivery of XIAP by SASTG vector ameliorates
apoptosis in rat neonatal cardiomyocytes
Some cardiomyopathies are associated with naturally oc-
curring viral infections such as adenovirus (Savon et al.,
2008). Apoptosis induced by these viral infections may con-
tribute to rapidly developing cardiomyopathies. Anticipat-
ing the use of the SASTG AAV-derived vector to deliver
XIAP to mitigate apoptotic effects in failing hearts, it was
prudent to evaluate the capacity of the SASTG vector to
FIG. 3. Evaluation of cardiac muscle transduction by AAV variants, using in vivo biophotonic imaging. (A) Cardiac muscle
transduction by AAV2-, T265-, and Q263AT265-luciferase vectors was examined on days 8, 15, 33, 60, and 90 postinjection. (B)
Cardiac muscle transduction by AAV1-, AAV3- and SASTG-luciferase vectors was examined on days 7 and 14 postinjection.
(C) Image showing in vivo expression of SASTG and AAV9 23 days after direct cardiac injection. Increasing wavelength reflects
greater luminescence. (D) Quantification of in vivo biophotonic imaging time course (days 2, 5, 12, 23), comparing luciferase
expression of AAV9 and SASTG injected directly into mouse myocardium. For each experiment: n = 4 mice per group and
2 · 109 genome particles of each vector was injected directly into the myocardium of each mouse. Data are expressed as relative
light units per region of interest (RLU/ROI). Color images available online at www.liebertonline.com/hum
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activate apoptosis in cardiomyocytes. Therefore, SASTG-
luciferase was compared with adenovirus-luciferase vectors
for their capacity to induce apoptosis in rat neonatal cardi-
omyocytes (Fig. 5). SASTG and adenoviral vectors were as-
sessed for transduction by measuring luciferase activity 24,
48, and 72 hr postinfection, using 100 particles/cell for ade-
novirus and 50,000 particles/cell for SASTG. Empirical
studies demonstrated that these were optimal doses to
achieve equivalent transduction efficiencies over time, as
demonstrated in Fig. 5A. Concomitantly, caspase-3/7 activ-
ity was assessed as a measure of apoptosis (Fig. 5B). Trans-
duction with SASTG vector induced substantially lower
levels of caspase-3/7 at all times, compared with adenoviral
vector (Fig. 5B). Most importantly, at the 72-hr time point
when SASTG and the adenoviral vector exhibited approxi-
mate equal transgene expression (Fig. 5A), caspase-3/7 ac-
tivity associated with the SASTG infection was 11.5-fold
lower than that observed with adenoviral transduction; a
distinction made obvious by the ratio of transduction relative
to caspase-3/7 activity (Fig. 5C). The nearly absent levels of
induced apoptosis combined with high transduction effi-
ciency make SASTG a suitable vehicle to deliver a transgene
that can interfere with apoptosis.
The aforementioned data suggest that XIAP may be a
therapeutic target for modulating apoptosis in heart failure.
The XIAP transgene was incorporated into the highly effi-
cient SASTG capsid and examined for the ability to attenuate
apoptosis in vitro. To determine whether increased expres-
sion of XIAP was protective, neonatal cardiomyocytes were
cultured and transduced with SASTG-XIAP, and compared
with SASTG-GFP as a control. Apoptosis was subsequently
induced by treatment of the cells with the protein kinase
C (PKC)-c inhibitor chelerythrine. Chelerythrine has been
shown to activate apoptosis through the intrinsic pathway,
resulting in cleavage of procaspase-3 (Yamamoto et al., 2001).
Figure 6 shows representative light microscopy photographs
of chelerythrine-exposed cardiomyocytes that had been
pretreated with SASTG-GFP (Fig. 6, left) or SASTG-XIAP
(Fig. 6, right). Note the paucity of cytoplasm and conden-
sation of the nuclei of the cardiomyocytes treated with
SASTG-GFP. In contrast, cardiomyocytes overexpressing
XIAP demonstrated robust cytoplasm volume with no ob-
vious condensation of the nuclei when exposed to cheler-
ythrine. These data indicate that apoptosis could be
effectively induced in cardiomyocytes in the absence of XIAP
protection.
The protective nature of XIAP in cardiomyocytes was
further assessed by measuring caspase-3/7 activity after
induction of apoptosis by three different cardiac stresses. In
accordance with data in Fig. 6, significantly less caspase-3/7
activity was observed after chelerythrine (CHEL) exposure
in cells expressing XIAP relative to cells transduced with
SASTG-GFP vector (Fig. 7). These data suggest that ex-
pression of XIAP attenuates apoptosis induced by PKC-c
inhibition. We also studied the effects of XIAP on b-adren-
ergically induced apoptosis, given that this signaling path-
way is believed to be the major inducer of apoptosis during
heart failure. Cardiomyocytes pretreated with SASTG-XIAP
were protected against caspase-3/7 activation after stimula-
tion with isoproterenol (ISO), compared with SASTG-GFP
control vector (Fig. 7). A third stress commonly encountered
in heart failure patients is hypoxia–ischemia (H/I). Apop-
tosis in neonatal cardiomyocytes was induced by exposure to
a hypoxic environment followed by reexposure to normal
medium and oxygen tension. Optimal conditions that induce
apoptosis were empirically determined. Similar to other
stresses, cardiomyocytes treated with SASTG-XIAP exhibited
significantly less caspase-3/7 activation compared with
SASTG-GFP control (Fig. 7). These data clearly demonstrate
that XIAP can ameliorate apoptosis induced in cardiomyo-
cytes by stresses associated with heart failure.
Discussion
Heart failure, the inability of the heart to pump sufficient
blood to meet the metabolic demands of the body, is an
important health problem in this country and worldwide. At
FIG. 4. Efficiency of SASTG
transduction in rat neonatal
cardiomyocytes (RNNCs).
Freshly isolated RNNCs were
transduced with AAV1-9 and
SASTG at 50,000 particles per
cell, all bearing the luciferase
transgene. The vectors were
applied to 10,000 cells in a 96-
well format. Light emitted
from the infections was as-
sayed by luminometry the
next day. These experiments
in RNNCs were repeated a
total of three times and data
similar to those shown in Fig.
4 were observed each time.
Data represent means and SD.
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present, limited numbers of drug-based therapies exist for
early-stage heart failure, and although these therapies limit
progression of heart failure, they do not prevent onset after
cardiac injury and these drugs often have adverse side effects
(e.g., hypotension). Furthermore, treatments for end-stage
heart failure including mechanical assist devices (e.g., a left
ventricular assist device [LVA]D) and orthotopic heart
transplantation are limited by high cost, bleeding, infection,
and/or donor supply. New and improved treatment strate-
gies are needed, and gene therapy is envisioned as one of the
FIG. 5. SASTG vectors exhibit reduced caspase-3/7 activation compared with adenoviral vectors in RNNCs. RNNCs were
infected with Ad-luciferase (100 particles per cell) or SASTG-luciferase (50,000 particles per cell). At 24, 48, and 72 hr
postinfection, equivalent protein amounts were used to assess luciferase activity (A), using the Promega luciferase assay
reagent, or (B) caspase-3/7 activity, using the Promega Caspase-Glo 3/7 assay system. Both assays were analyzed with a
Veritas luminometer from Turner Biosystems. (C) The ratio of vector-expressed luciferase to caspase-3/7 activity is shown.
Each time point was examined in triplicate. Data represent means – SD.
FIG. 6. SASTG-mediated delivery of XIAP
ameliorates apoptosis in RNNCs. Shown are
photographs of RNNCs treated with cheler-
ythrine 72 hr posttreatment with SASTG-
XIAP (right) or SASTG-GFP (left). The cell
membrane is outlined in selected cells (ar-
rows) to emphasize the attenuation of cyto-
plasm and to pinpoint nuclei in RNNCs
exposed to chelerythrine without SASTG-
XIAP transduction, suggestive of activation
of apoptosis.
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most promising therapeutic options for heart failure. Ac-
cording to Kratlian and Hajjar, three main factors are nec-
essary for successful gene therapy: (1) a molecular target
appropriate for the disease, (2) successful vector design, and
(3) targeted delivery methods (Kratlian and Hajjar, 2012).
Here we describe a new molecular target, the X-linked in-
hibitor of apoptosis protein (XIAP), for cardiac gene therapy
as well as optimization of the AAV capsid design for en-
hanced cardiac gene delivery.
We first demonstrate that the molecular target XIAP, a
potent inhibitor of apoptosis, is reduced in failing human
hearts, compared with nonfailing human hearts (Fig. 1).
Previous reports have been inconsistent in demonstrating
changes in myocardial XIAP levels in failing versus non-
failing human samples (Scheubel et al., 2002; Haider et al.,
2009). In our study, XIAP levels were detected and quanti-
tated by two independent methods. Care was taken to
standardize tissue procurement and storage, and nonfailing
control samples were matched for age and sex. We show
definitively that XIAP levels are diminished in human heart
failure. Correspondingly, the activity of a late marker of
apoptosis, caspase-3/7, was increased in failing human
hearts. The most important proapoptotic enzymes, caspases
3, 8, and 9, were previously demonstrated to progressively
increase in activity during the transition from preserved LV
function to heart failure in porcine myocardium (Moorjani
et al., 2009). Perhaps the most convincing evidence for the
involvement of apoptosis in heart failure originates from a
study examining the number of apoptotic nuclei in trans-
genic mice expressing a conditionally active form of caspase-
8 specifically in the myocardium, wherein a low apoptotic
index of 0.23 was sufficient to cause lethal dilated cardio-
myopathy (Wencker et al., 2003). Other cardiac stresses that
appear to be early triggers for increased apoptosis in the
myocardium include increases in LV pressure and volume
overload (Cheng et al., 1995; Abbate et al., 2003; Yankey et al.,
2008). Furthermore, b-adrenergic antagonists and angiotensin-
converting enzyme inhibitors, the most important clinical
medications for early heart failure, have been shown to reduce
myocardial apoptosis (Kajstura et al., 1997; Romeo et al., 2000;
Rossig et al., 2000).
Therefore, methods to inhibit the activities of proapoptotic
caspases are promising therapeutic options in the treatment
of heart failure. A clear understanding of the amounts, ac-
tivities, and regulation of inhibitors of proapoptotic proteins
in the human heart and heart failure models are crucial to the
development of antiapoptotic gene therapy treatments for
heart failure. Because XIAP is a potent inhibitor of proa-
poptotic caspases that is diminished during heart failure, a
logical therapeutic approach would be to augment XIAP
expression through in vivo delivery to cardiomyocytes. AAV-
derived vectors are increasingly receiving U.S. Food and
Drug Administration (FDA) approval for therapeutic gene
delivery in a number of clinical trials (Mingozzi and High,
2011). The success of these vectors in clinical trials was em-
phasized at a national meeting (Kaiser, 2011). The rational
design of AAV2 into a vector, AAV2.5, with enhanced
skeletal muscle transduction was used in a clinical trial for
muscular dystrophy (Bowles et al., 2011). The rationale for
the development of AAV2.5 was derived from amino acid
alignments of capsids from serotypes that transduce skeletal
muscle with high efficiency (AAV1, AAV7, AAV8, AAV9),
compared with those that are inefficient (AAV2, AAV3b)
(Xiao et al., 1999; Chao et al., 2000, 2001; Louboutin et al.,
2005; Wu et al., 2006). These alignments, together with the
atomic structure of the AAV2 capsid, revealed five amino
acid sites in AAV2 that were genetically modified via re-
placement or insertion of the corresponding amino acids
from AAV1, yielding AAV2.5. In the current study we have
narrowed this region, demonstrating that a single amino acid
insertion, T265, in the AAV2 capsid is sufficient to enhance
skeletal muscle transduction to a level similar to AAV2.5
(Fig. 2B). Notably, the enhanced transduction profile ob-
served by transfer of these particular amino acids was not
restricted to the AAV2 capsid, as demonstrated by enhanced
skeletal muscle transduction of the SASTG vector derived
from AAV3b (Fig. 2C and D). Apparently, the Q263A/T265
modifications comprise a portable system that can modulate
the transduction properties of at least AAV2 and AAV3b,
possibly extending to other AAVs. These data indicate that
the Q263A/T265 modifications may alter the capsid struc-
tural properties of AAV2 and AAV3b at the 2-fold axis of
symmetry during the transduction process. Most impor-
tantly, however, the SASTG vector dramatically exceeded
the transduction efficiency of AAV1, AAV9, and subvariants
of AAV2 during in vivo transduction of the heart (Fig. 3).
Moreover, SASTG was most efficient at transducing primary
neonatal rat cardiomyocytes when evaluated against a panel
of conventional AAV vectors (Fig. 4). The high efficiency of
heart and cardiomyocyte transduction makes SASTG a
promising candidate for delivery of therapeutic transgenes to
cardiac tissue.
By employing the attributes of SASTG, we may be able to
deliver antiapoptotic proteins, such as XIAP, to abate the
FIG. 7. Pretreatment of RNNCs with SASTG-XIAP vector
diminishes caspase-3/7 activation after exposure to three
types of apoptotic inducers. RNNCs (10,000 cells per well)
were transduced with SASTG-GFP or SASTG-XIAP (20,000
particles/cell). Treatments to induce apoptosis (chelerythrine
[CHEL], isoproterenol [ISO], hypoxia–ischemia [H/I]) were
performed on cells approximately 72 hr posttransduction in
triplicate. CHEL was added to the medium for 1 hr at a final
concentration of 1 lM. ISO (1 lM) was added to the medium
for 24 hr. H/I was induced by placing cells in an airtight
container at 37C and altering the O2 concentration over a
24-hr period. Cells from all experiments were lysed and
assayed for caspase-3/7 activity, and normalized to total
protein. *p < 0.05.
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effects of apoptosis in diseased hearts. Therefore, a vector
offering minimal apoptosis induction would be advanta-
geous. We compared transgene expression and caspase-3/7
activation after transduction with either SASTG or an ade-
noviral vector. Adenoviral vectors can be toxic to cardiac
myocytes, and part of the toxicity might be due to apoptosis
induction. Certain cardiomyopathies are in fact associated
with adenoviral infections (Savon et al., 2008). We show
comparatively that SASTG vectors induced significantly less
activation of the caspase cascade relative to adenoviral vectors
while at the same time retaining high levels of transgene ex-
pression (Fig. 5). These data suggest that in the absence of any
other stimuli, adenoviral vectors activated the apoptotic cas-
cade in cultured neonatal cardiac myocytes. Accordingly, the
SASTG vector offers the greatest transgene expression with
the least induction of apoptosis. This finding is consistent with
those of Stilwell and colleagues, who have demonstrated that
AAV vectors minimally perturb cellular gene transcription
when compared with adenoviral vectors (Stilwell et al., 2003;
Stilwell and Samulski, 2004). On the basis of the attributes of
SASTG, this vector was employed to deliver XIAP to primary
rat neonatal cardiomyocytes. Cardiomyocytes expressing
XIAP were significantly protected from apoptosis induced by
three different cardiac stresses (Figs. 6 and 7).
Here we provide the initial proof-of-principle experiments
that lay the groundwork to use XIAP as a possible therapy
for ischemia–reperfusion injury and the deleterious re-
modeling that can lead to heart failure. Furthermore, we
report the development of the SASTG AAV vector, which
exhibits a highly efficient cardiac transduction profile with
minimal activation of the apoptotic cascade. Coupled with
the minimal activation of caspase-3/7, SASTG-XIAP appears
to be an efficient vector for attenuation of apoptosis in car-
diac myocytes. Our future work will comprise animal studies
to derive the true translational value of SASTG-XIAP for
potential heart failure therapy.
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